| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
26,320,000 |
| Market
Cap: |
3.83(M) |
| Last
Volume: |
169,426 |
Avg
Vol: |
168,958 |
| 52
Week Range: |
$0.1454 - $0.1454 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Co. is developing multiple precision-targeted products based on its Manocept™ platform to improve patient care by identifying the sites and pathways of undetected disease and enable diagnostic, clinical decision-making and targeted treatment. Co.'s business is focused on two primary types of drug products: diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, including therapeutic applications of its Manocept platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Regan William J. |
SVP-Global Regulatory Strategy |
• – – |
2014-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
30,000 |
|
- |
|
| Goldberg Michael M |
Director |
– • – |
2014-11-14 |
4 |
B |
$1.12 |
$31,890 |
D/D |
28,359 |
289,711 |
2.39 |
- |
|
| Goldberg Michael M |
Director |
– • – |
2014-11-13 |
4 |
B |
$1.06 |
$75,853 |
D/D |
71,641 |
261,352 |
2.39 |
- |
|
| Ford Brendan A |
Director |
– • – |
2014-11-10 |
4 |
B |
$1.03 |
$10,300 |
D/D |
10,000 |
180,696 |
2.39 |
- |
|
| Ford Brendan A |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$15,109 |
D/D |
11,446 |
170,696 |
|
- |
|
| Drake Peter F |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$14,484 |
D/D |
10,973 |
70,223 |
|
- |
|
| Goldberg Michael M |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$12,500 |
D/D |
9,470 |
189,711 |
|
- |
|
| Karsen Perry A |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$13,533 |
D/D |
10,252 |
30,252 |
|
- |
|
| Troup Gordon A |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$21,251 |
D/D |
16,099 |
182,349 |
|
- |
|
| Rowinsky Eric K |
Director |
– • – |
2014-11-10 |
4 |
A |
$1.32 |
$12,500 |
D/D |
9,470 |
163,720 |
|
- |
|
| Tulip Thomas H. |
President |
• – – |
2014-10-06 |
4 |
D |
$1.34 |
$8,820 |
D/D |
(6,582) |
58,418 |
|
- |
|
| Tulip Thomas H. |
President |
• – – |
2014-10-06 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
65,000 |
|
- |
|
| Platinum-Montaur Life Sciences, Llc |
10% Owner |
– – • |
2014-09-02 |
4 |
S |
$1.36 |
$81,552 |
I/I |
(60,000) |
14,946,431 |
|
- |
|
| Platinum Partners Liquid Opportunity Master Fund L |
10% Owner |
– – • |
2014-08-12 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
15,106,431 |
|
- |
|
| Pykett Mark Jerome |
Director |
• • – |
2014-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
312,674 |
|
- |
|
| Regan William J. |
SVP-Global Reg Affairs&Quality |
• • – |
2014-05-12 |
4 |
B |
$1.43 |
$7,139 |
D/D |
5,000 |
10,000 |
2.74 |
- |
|
| Pykett Mark Jerome |
CEO |
• • – |
2014-05-09 |
4 |
B |
$1.34 |
$13,400 |
D/D |
10,000 |
292,674 |
2.81 |
- |
|
192 Records found
|
|
Page 8 of 8 |
|
|
